Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00829231 · ClinicalTrials.gov registry record · Phase 1
Hepatic Impairment Study
A Phase 1 study of Liver Disease, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 3
- Study locations
NCT00829231 is a Phase 1 study of Liver Disease that has completed, run by Bayer. The registered enrollment target is 45 participants, below the 792-participant average among 14 other Liver Disease trials with a reported enrollment target (94% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT00829231, a Phase 1 study of Liver Disease, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is to find out how the subject's body processes and reacts to the study drug, and to find out how long it remains in the subjects system after one dose. Subjects with varying degrees of liver function are being asked to participate in this study. Study results from subjects with normal liver function will be compared with study results from subjects with impaired liver function.
Conditions Studied
Interventions
- DRUG Sorafenib (Nexavar, BAY43-9006)
Study Locations (3)
Florida
- - Miami
- - Orlando
Tennessee
- - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00829231
The ClinicalTrials.gov registry entry for NCT00829231 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 792-participant average among 14 other Liver Disease trials with a reported enrollment target (94% lower). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Liver Disease appearing as the primary indexed condition, and to 1 intervention - of which Sorafenib (Nexavar, BAY43-9006) is the first listed.
NCT00829231 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Florida, Tennessee.
Frequently Asked Questions
What is clinical trial NCT00829231 about?
NCT00829231 is a clinical study titled "Hepatic Impairment Study". This study is to find out how the subject's body processes and reacts to the study drug, and to find out how long it remains in the subjects system after one dose. Subjects with varying degrees of liver function are being asked to participate in this study. Study results from subjects with normal li...
What is the current status of trial NCT00829231?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2009-01. Estimated completion is 2009-07.
What conditions does trial NCT00829231 study?
This clinical trial studies the following conditions: Liver Disease.
What interventions are being tested in trial NCT00829231?
The interventions under investigation include: Sorafenib (Nexavar, BAY43-9006) (DRUG).
Who is sponsoring clinical trial NCT00829231?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00829231 being conducted?
This trial has 3 study locations across Florida, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients
COMPLETED · Phase 1
-
A Phase 1 Study to Compare the PK and Safety of Naproxcinod in Hepatic Impaired Patients and Matching Healthy Subjects
COMPLETED · Phase 1
-
Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver Function
COMPLETED · Phase 1
-
Evaluation of Patients With Liver Disease
RECRUITING
-
Genetic Modifiers of Cystic Fibrosis (CF) Liver Disease
ACTIVE NOT RECRUITING
-
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.